RXRX · Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals issued its Q1 2026 earnings press release on May 6, 2026, focusing on pipeline progress rather than detailed income statement figures. Key clinical highlights include REC-1245, an RBM39 degrader for solid tumors and lymphoma, showing a well-tolerated profile in early Phase 1 monotherapy dose escalation across 16 patients with advanced solid tumors. No dose-limiting toxicities were observed, with 90%+ of treatment-related adverse events being Grade 1 or 2, primarily GI-related and fatigue; pharmacokinetics were predictable and dose-dependent, supporting once-daily dosing. REC-4881 demonstrated strong Phase 2 efficacy in familial adenomatous polyposis (FAP), targeting underlying APC biology with rapid polyp reductions, prompting FDA engagement for a potential registrational pathway and an update expected in 2H26. REC-4539, an LSD1 inhibitor, dosed its first patient in Phase 1, differentiated by reversible mechanism to mitigate platelet toxicity and brain penetrance for CNS metastases. The company reiterated 2026 guidance of $500M in partner inflows and delivery of 10+ milestones, underscoring the AI-native product engine's output across wholly owned and partnered programs with Sanofi, Roche, and Genentech. Capital discipline is evident with cash runway into early 2028 and 30% YoY reduction in cash operating expenses, pairing pipeline advancement with rigorous execution. Leadership strengthened with Vicki Goodman, M.D., as new CMO, bringing FDA and Big Pharma experience in oncology approvals like KEYTRUDA and OPDIVO. These updates validate platform-derived targets and position Recursion for near-term catalysts in oncology and rare diseases.